Table 2. Comparison of expression of autophagy markers LC3B and p62 in primary resected and neo-adjuvant chemotherapy (nCTX) treated EAC cohorts.

Significance was set to 0.05. Statistically significant p-values are shown in bold.

LC3B dots	Treatment			Total
	Primary Resected	nCTX
		Response	Nonresponse
Low	95	21	41	157
High	19	8	13	40
Total	114	29	54	197
Treatment Naïve vs. Chemotherapy: p-value = 0.154
Response vs Nonresponse: p-value = 0.794
p62 dots	Treatment			Total
	Primary Resected	nCTX
		Response	Nonresponse
Low	95	18	26	139
High	19	11	28	58
Total	114	29	54	197
Treatment Naïve vs. Chemotherapy: p-value < 0.001
Response vs Nonresponse: p-value = 0.256
p62 cytoplasmic	Treatment			Total
	Primary Resected	nCTX
		Response	Nonresponse
Low	86 (75.4%)	21 (72.4%)	17 (31.5%)	124 (62.9%)
High	28 (24.6%)	8 (27.6%)	37 (68.5%)	73 (37.1%)
Total	114	29	54	197
Treatment Naïve vs. Chemotherapy: p-value < 0.001
Response vs Nonresponse: p-value < 0.001
p62 nuclear	Treatment			Total
	Primary Resected	nCTX
		Response	Nonresponse
Low	58 (50.9%)	17 (58.6%)	39 (72.2%)	114 (57.9%)
High	56 (49.1%)	12 (41.4%)	15 (27.8%)	83 (42.1%)
Total	114	29	54	197
Treatment Naïve vs. Chemotherapy: p-value = 0.028
Response vs Nonresponse: p-value = 0.228
p62 dots-cyto	Treatment			Total
	Primary Resected	nCTX
		Response	Nonresponse
Low	76 (66.7%)	14 (48.3%)	10 (18.5%)	100 (50.8%)
High	38 (33.3%)	15 (51.7%)	44 (81.5%)	97 (49.2%)
Total	114	29	54	197
Treatment Naïve vs. Chemotherapy: p-value = 0.006
Response vs Nonresponse: p-value < 0.001
LCB/p62	Treatment			Total
	Primary Resected	nCTX
		Response	Nonresponse
LL	66 (57.9%)	11 (38.0%)	9 (16.7%)	86 (43.7%)
LH	29 (25.4%)	10 (34.5%)	32 (59.3%)	71 (36.0%)
HL	10 (8.8%)	3 (10.3%)	1 (1.8%)	14 (7.1%)
HH	9 (7.9%)	5 (17.2%)	12 (22.2%)	26 (13.2%)
Total	114	29	54	197
Treatment Naïve vs. Chemotherapy: p-value < 0.001
Response vs Nonresponse: p-value = 0.034